AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Transact Technologies Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Artiva Biotherapeutics (ARTV) filed a Form 8-K on August 6, 2025. Under Item 2.02, the company disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is expressly not deemed “filedâ€� for liability purposes under Section 18 of the Exchange Act. Item 9.01 lists the exhibits included in the filing, namely the press release and the cover-page Inline XBRL data file. No actual financial figures, guidance, or narrative commentary are contained within the 8-K itself.

The filing is procedural, serving mainly to make the earnings release publicly available while limiting legal exposure. Investors must review Exhibit 99.1 for quantitative details.

Artiva Biotherapeutics (ARTV) ha presentato un modulo 8-K il 6 agosto 2025. Ai sensi della voce 2.02, la società ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari del trimestre terminato il 30 giugno 2025. Il comunicato stampa è allegato come Exhibit 99.1 e non è considerato "depositato" ai fini di responsabilità secondo la Sezione 18 del Exchange Act. La voce 9.01 elenca gli allegati inclusi nella presentazione, ovvero il comunicato stampa e il file di dati Inline XBRL della pagina di copertina. Il modulo 8-K non contiene dati finanziari effettivi, previsioni o commenti narrativi.

La presentazione è di natura procedurale, servendo principalmente a rendere pubblico il comunicato sugli utili limitando l’esposizione legale. Gli investitori devono consultare l’Exhibit 99.1 per i dettagli quantitativi.

Artiva Biotherapeutics (ARTV) presentó un Formulario 8-K el 6 de agosto de 2025. Bajo el punto 2.02, la empresa informó que emitió un comunicado de prensa anunciando los resultados financieros del trimestre finalizado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y no se considera "presentado" para efectos de responsabilidad según la Sección 18 del Exchange Act. El punto 9.01 enumera los anexos incluidos en la presentación, que son el comunicado de prensa y el archivo de datos Inline XBRL de la portada. El 8-K en sí no contiene cifras financieras reales, pronósticos ni comentarios narrativos.

La presentación es de carácter procedimental, sirviendo principalmente para hacer público el comunicado de resultados mientras limita la exposición legal. Los inversores deben revisar el Exhibit 99.1 para obtener detalles cuantitativos.

Artiva Biotherapeutics(ARTV)ëŠ� 2025ë…� 8ì›� 6ì¼ì— Form 8-Kë¥� 제출했습니다. 항목 2.02ì—� ë”°ë¼, 회사ëŠ� 2025ë…� 6ì›� 30ì� 종료ë� 분기ì� 재무 ê²°ê³¼ë¥� 발표하는 ë³´ë„ ìžë£Œë¥� 발행했다ê³� 공시했습니다. 해당 ë³´ë„ ìžë£ŒëŠ� Exhibit 99.1ë¡� 제공ë˜ë©°, Exchange Act 섹션 18ì—� 따른 ì±…ìž„ 목ì ìƒ� "제출ë�"으로 간주ë˜ì§€ 않습니다. 항목 9.01ì—는 ì œì¶œë¬¼ì— í¬í•¨ë� ìžë£Œë“¤ì´ 나열ë˜ì–´ 있는ë�, ë³´ë„ ìžë£Œì™€ 표지 페ì´ì§€ Inline XBRL ë°ì´í„� 파ì¼ìž…니ë‹�. 8-K ìžì²´ì—는 실제 재무 수치, ê°€ì´ë“œë¼ì¸ ë˜ëŠ” 서술ì � 설명ì� í¬í•¨ë˜ì–´ 있지 않습니다.

ì´ë²ˆ ì œì¶œì€ ì ˆì°¨ì ì¸ 성격으로, 주로 ì‹¤ì  ë°œí‘œë¥� 공개하면ì„� ë²•ì  ì±…ìž„ì� 제한하는 ì—­í• ì� 합니ë‹�. 투ìžìžë“¤ì€ 정량ì � 세부사항ì� 위해 Exhibit 99.1ì� 검토해ì•� 합니ë‹�.

Artiva Biotherapeutics (ARTV) a déposé un formulaire 8-K le 6 août 2025. Selon l'article 2.02, la société a annoncé la publication d'un communiqué de presse présentant les résultats financiers du trimestre clos le 30 juin 2025. Ce communiqué est fourni en tant qu'Exhibit 99.1 et n'est expressément pas considéré comme "déposé" aux fins de responsabilité en vertu de la section 18 du Exchange Act. L'article 9.01 énumère les annexes incluses dans le dépôt, à savoir le communiqué de presse et le fichier de données Inline XBRL de la page de couverture. Le formulaire 8-K lui-même ne contient pas de chiffres financiers réels, de prévisions ou de commentaires narratifs.

Ce dépôt est de nature procédurale, servant principalement à rendre la publication des résultats accessible au public tout en limitant l'exposition juridique. Les investisseurs doivent consulter l'Exhibit 99.1 pour les détails quantitatifs.

Artiva Biotherapeutics (ARTV) reichte am 6. August 2025 ein Formular 8-K ein. Unter Punkt 2.02 gab das Unternehmen bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht hat. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird ausdrücklich nicht im Sinne der Haftung gemäß Abschnitt 18 des Exchange Act als "eingereicht" angesehen. Punkt 9.01 listet die im Einreichungsdokument enthaltenen Anlagen auf, nämlich die Pressemitteilung und die Inline-XBRL-Datendatei der Titelseite. Das 8-K selbst enthält keine tatsächlichen Finanzzahlen, Prognosen oder erläuternde Kommentare.

Die Einreichung ist prozedural und dient hauptsächlich dazu, die Gewinnmitteilung öffentlich zugänglich zu machen und gleichzeitig die rechtliche Haftung zu begrenzen. Anleger müssen Exhibit 99.1 für quantitative Details prüfen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 8-K furnishes Q2-25 earnings release; no numbers disclosed here.

The 8-K is purely administrative, triggering no immediate valuation insight because it omits the underlying financial metrics. Management uses Item 2.02 to ensure Reg FD compliance while keeping the furnished material outside Section 18 liability. Impact on the stock will depend entirely on the content of Exhibit 99.1, which is not provided. Therefore, the filing itself is neutral and non-impactful from an analytical standpoint.

Artiva Biotherapeutics (ARTV) ha presentato un modulo 8-K il 6 agosto 2025. Ai sensi della voce 2.02, la società ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari del trimestre terminato il 30 giugno 2025. Il comunicato stampa è allegato come Exhibit 99.1 e non è considerato "depositato" ai fini di responsabilità secondo la Sezione 18 del Exchange Act. La voce 9.01 elenca gli allegati inclusi nella presentazione, ovvero il comunicato stampa e il file di dati Inline XBRL della pagina di copertina. Il modulo 8-K non contiene dati finanziari effettivi, previsioni o commenti narrativi.

La presentazione è di natura procedurale, servendo principalmente a rendere pubblico il comunicato sugli utili limitando l’esposizione legale. Gli investitori devono consultare l’Exhibit 99.1 per i dettagli quantitativi.

Artiva Biotherapeutics (ARTV) presentó un Formulario 8-K el 6 de agosto de 2025. Bajo el punto 2.02, la empresa informó que emitió un comunicado de prensa anunciando los resultados financieros del trimestre finalizado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y no se considera "presentado" para efectos de responsabilidad según la Sección 18 del Exchange Act. El punto 9.01 enumera los anexos incluidos en la presentación, que son el comunicado de prensa y el archivo de datos Inline XBRL de la portada. El 8-K en sí no contiene cifras financieras reales, pronósticos ni comentarios narrativos.

La presentación es de carácter procedimental, sirviendo principalmente para hacer público el comunicado de resultados mientras limita la exposición legal. Los inversores deben revisar el Exhibit 99.1 para obtener detalles cuantitativos.

Artiva Biotherapeutics(ARTV)ëŠ� 2025ë…� 8ì›� 6ì¼ì— Form 8-Kë¥� 제출했습니다. 항목 2.02ì—� ë”°ë¼, 회사ëŠ� 2025ë…� 6ì›� 30ì� 종료ë� 분기ì� 재무 ê²°ê³¼ë¥� 발표하는 ë³´ë„ ìžë£Œë¥� 발행했다ê³� 공시했습니다. 해당 ë³´ë„ ìžë£ŒëŠ� Exhibit 99.1ë¡� 제공ë˜ë©°, Exchange Act 섹션 18ì—� 따른 ì±…ìž„ 목ì ìƒ� "제출ë�"으로 간주ë˜ì§€ 않습니다. 항목 9.01ì—는 ì œì¶œë¬¼ì— í¬í•¨ë� ìžë£Œë“¤ì´ 나열ë˜ì–´ 있는ë�, ë³´ë„ ìžë£Œì™€ 표지 페ì´ì§€ Inline XBRL ë°ì´í„� 파ì¼ìž…니ë‹�. 8-K ìžì²´ì—는 실제 재무 수치, ê°€ì´ë“œë¼ì¸ ë˜ëŠ” 서술ì � 설명ì� í¬í•¨ë˜ì–´ 있지 않습니다.

ì´ë²ˆ ì œì¶œì€ ì ˆì°¨ì ì¸ 성격으로, 주로 ì‹¤ì  ë°œí‘œë¥� 공개하면ì„� ë²•ì  ì±…ìž„ì� 제한하는 ì—­í• ì� 합니ë‹�. 투ìžìžë“¤ì€ 정량ì � 세부사항ì� 위해 Exhibit 99.1ì� 검토해ì•� 합니ë‹�.

Artiva Biotherapeutics (ARTV) a déposé un formulaire 8-K le 6 août 2025. Selon l'article 2.02, la société a annoncé la publication d'un communiqué de presse présentant les résultats financiers du trimestre clos le 30 juin 2025. Ce communiqué est fourni en tant qu'Exhibit 99.1 et n'est expressément pas considéré comme "déposé" aux fins de responsabilité en vertu de la section 18 du Exchange Act. L'article 9.01 énumère les annexes incluses dans le dépôt, à savoir le communiqué de presse et le fichier de données Inline XBRL de la page de couverture. Le formulaire 8-K lui-même ne contient pas de chiffres financiers réels, de prévisions ou de commentaires narratifs.

Ce dépôt est de nature procédurale, servant principalement à rendre la publication des résultats accessible au public tout en limitant l'exposition juridique. Les investisseurs doivent consulter l'Exhibit 99.1 pour les détails quantitatifs.

Artiva Biotherapeutics (ARTV) reichte am 6. August 2025 ein Formular 8-K ein. Unter Punkt 2.02 gab das Unternehmen bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht hat. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird ausdrücklich nicht im Sinne der Haftung gemäß Abschnitt 18 des Exchange Act als "eingereicht" angesehen. Punkt 9.01 listet die im Einreichungsdokument enthaltenen Anlagen auf, nämlich die Pressemitteilung und die Inline-XBRL-Datendatei der Titelseite. Das 8-K selbst enthält keine tatsächlichen Finanzzahlen, Prognosen oder erläuternde Kommentare.

Die Einreichung ist prozedural und dient hauptsächlich dazu, die Gewinnmitteilung öffentlich zugänglich zu machen und gleichzeitig die rechtliche Haftung zu begrenzen. Anleger müssen Exhibit 99.1 für quantitative Details prüfen.

false 0001017303 0001017303 2025-08-05 2025-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 5, 2025

 

 

 

TransAct Technologies Incorporated

(Exact name of registrant as specified in its charter)

 

 

Delaware 0-21121 06-1456680
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

One Hamden Center  
2319 Whitney Ave, Suite 3B, Hamden, CT 06518
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (203) 859-6800

 

(Former name or former address, if changed since last report): Not applicable

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $.01 per share TACT NASDAQ Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  
 

 

Item 1.01Entry into a Material Definitive Agreement.

 

On August 5, 2025, TransAct Technologies Incorporated (the “Company”) entered into a Source Code Purchase and Perpetual License Agreement (the “License Agreement”) and a related Transition Statement of Work (the “SOW,” and together with the License Agreement, the “Source Code Transition Agreement”) with Avery Dennison Corporation (“Avery Dennison”).

 

Pursuant to the Source Code Transition Agreement, the Company has acquired a non-exclusive, perpetual and royalty free license to a copy of the source code and associated documentation for the BOHA™ Control Center, BOHA™ Ops (including labeling, media, checklist and timer modules), and the BOHA™ Temp and BOHA™ Sense applications (the “Code”), subject to payment by the Company of the full purchase price of $2.55 million (“Purchase Price”).

 

This license allows the Company to use, modify, market, host, distribute, sublicense, copy and create derivative works of the Code for the Company’s business purposes. The Company will own any modifications it creates during the term of the Source Code Transition Agreement as well as after completion of the transition services, subject to claw-back if the Company fails to pay the Purchase Price and the professional fees for the transition services as described below. Any modifications that Avery Dennison develops during the performance of the transition services will be owned by Avery Dennison but are automatically included in the Code licensed to the Company.

 

The SOW sets out the milestones for the transition services, including delivery of source code and technical documentation; build pipeline set-up; hosting environment configuration; application training and monitoring; data cutover validation and 90 days of post-migration support phase.

 

Pursuant to the Source Code Transition Agreement, the Company will pay Avery Dennison the $2.55 million Purchase Price in three milestone installments. The first installment of $1.0 million is payable on the effective date of the Source Code Transition Agreement; the second installment of $0.775 million is payable upon acceptance of the hosting environment configuration phase under the SOW; and the third and final installment of $0.775 million is payable at the earlier of (i) completion of the support phase under the SOW and (ii) 12 months after the effective date of the Source Code Transition Agreement. In addition, in consideration for the transition services under the SOW, the Company will pay Avery Dennison fixed professional services fees of $1.007 million, in installments tied to project phases that run from Code delivery through platform cutover, support and data migration.

 

The foregoing description of the Source Code Transition Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Source Code Transition Agreement. A copy of the Source Code Transition Agreement is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

 

Item 2.02Results of Operations and Financial Condition.

 

The following information is being furnished pursuant to Item 2.02 “Results of Operations and Financial Condition” of Form 8-K.  Such information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

On August 6, 2025, the Company issued a press release announcing its financial results for the quarter ended June 30, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report.

 

Item 8.01Other Events.

 

On August 6, 2025, the Company issued a press release announcing the entry into the Source Code Transition Agreement. A copy of the press release is attached as Exhibit 99.2 to this report and is incorporated herein by reference.

 

  
 

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit   Description
10.1†   Source Code Purchase and Perpetual License Agreement, dated as of August 5, 2025, by and between TransAct Technologies Incorporated and Avery Dennison Corporation.
99.1   Press Release dated August 6, 2025 of TransAct Technologies Incorporated announcing financial results for the quarter ended June 30, 2025.
99.2   Press Release dated August 6, 2025 of TransAct Technologies Incorporated announcing entry into Source Code Purchase and Perpetual License Agreement.
104   Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10) of Regulation S-K.

 

  
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  TRANSACT TECHNOLOGIES INCORPORATED
     
  By: /s/ Steven A. DeMartino
    Steven A. DeMartino
    President, Chief Financial Officer, Treasurer and Secretary

 

Date: August 6, 2025

 

 

 

 

 

 

Transact Tech

NASDAQ:TACT

TACT Rankings

TACT Latest News

TACT Latest SEC Filings

TACT Stock Data

38.91M
8.94M
11.27%
56.05%
0.08%
Computer Hardware
Computer Peripheral Equipment, Nec
United States
HAMDEN